Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Association between C-reactive protein and survival in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003
C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis Source: Eur Respir J 2001; 18: Suppl. 33, 65s Year: 2001
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
Plasma D-dimer level and stage of primary lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003
CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005
Serum levels of sFas and sFasL during chemotherapy of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005
Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011
Elevated level of circulating matrix metalloproteinase-9 in non-small lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 229s Year: 2002
Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004
The study on the association of serum C-reactive protein level with the risk of lung cancer Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours Year: 2009
Serum hepcidin and iron are associated with non-small cell lung cancer stage Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
Evaluation of serum levels of Sirtuin-1 in lung cancer patients Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002